Day Range2.680 - 2.800 | 52 Wk Range2.350 - 8.180 | Open / Close2.780 / - | Float / Outstanding18.241M / 31.827M |
Vol / Avg.15.924K / 66.137K | Mkt Cap88.151M | P/E- | 50d Avg. Price3.090 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float18.241M | EPS-2.520 |
Lyra Therapeutics Stock (NASDAQ: LYRA) stock price, news, charts, stock research, profile.
Day Range2.680 - 2.800 | 52 Wk Range2.350 - 8.180 | Open / Close2.780 / - | Float / Outstanding18.241M / 31.827M |
Vol / Avg.15.924K / 66.137K | Mkt Cap88.151M | P/E- | 50d Avg. Price3.090 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float18.241M | EPS-2.520 |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-03-08 | ||||||
REV |
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.440 | -0.400 | 0.0400 | ||||
REV | 140.000K | 359.000K | 219.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Lyra Therapeutics (NASDAQ: LYRA) through any online brokerage.
Other companies in Lyra Therapeutics’s space includes: Opiant Pharma (NASDAQ:OPNT), SCYNEXIS (NASDAQ:SCYX), Ocuphire Pharma (NASDAQ:OCUP), Longboard Pharmaceuticals (NASDAQ:LBPH) and Qilian Intl Hldg Gr (NASDAQ:QLI).
The latest price target for Lyra Therapeutics (NASDAQ: LYRA) was reported by Cantor Fitzgerald on Tuesday, May 24, 2022. The analyst firm set a price target for 15.00 expecting LYRA to rise to within 12 months (a possible 441.57% upside). 1 analyst firms have reported ratings in the last year.
The stock price for Lyra Therapeutics (NASDAQ: LYRA) is $2.7697 last updated Today at January 31, 2023 at 3:39 PM UTC.
There are no upcoming dividends for Lyra Therapeutics.
Lyra Therapeutics’s Q4 earnings are confirmed for Wednesday, March 8, 2023.
There is no upcoming split for Lyra Therapeutics.
Lyra Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
Lyra Therapeutics Stock (NASDAQ: LYRA) stock price, news, charts, stock research, profile.
Day Range2.680 - 2.800 | 52 Wk Range2.350 - 8.180 | Open / Close2.780 / - | Float / Outstanding18.241M / 31.827M |
Vol / Avg.15.924K / 66.137K | Mkt Cap88.151M | P/E- | 50d Avg. Price3.090 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float18.241M | EPS-2.520 |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-03-08 | ||||||
REV |
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.440 | -0.400 | 0.0400 | ||||
REV | 140.000K | 359.000K | 219.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Lyra Therapeutics (NASDAQ: LYRA) through any online brokerage.
Other companies in Lyra Therapeutics’s space includes: Opiant Pharma (NASDAQ:OPNT), SCYNEXIS (NASDAQ:SCYX), Ocuphire Pharma (NASDAQ:OCUP), Longboard Pharmaceuticals (NASDAQ:LBPH) and Qilian Intl Hldg Gr (NASDAQ:QLI).
The latest price target for Lyra Therapeutics (NASDAQ: LYRA) was reported by Cantor Fitzgerald on Tuesday, May 24, 2022. The analyst firm set a price target for 15.00 expecting LYRA to rise to within 12 months (a possible 441.57% upside). 1 analyst firms have reported ratings in the last year.
The stock price for Lyra Therapeutics (NASDAQ: LYRA) is $2.7697 last updated Today at January 31, 2023 at 3:39 PM UTC.
There are no upcoming dividends for Lyra Therapeutics.
Lyra Therapeutics’s Q4 earnings are confirmed for Wednesday, March 8, 2023.
There is no upcoming split for Lyra Therapeutics.
Lyra Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
Lyra Therapeutics Stock (NASDAQ: LYRA) stock price, news, charts, stock research, profile.
Day Range2.680 - 2.800 | 52 Wk Range2.350 - 8.180 | Open / Close2.780 / - | Float / Outstanding18.241M / 31.827M |
Vol / Avg.15.924K / 66.137K | Mkt Cap88.151M | P/E- | 50d Avg. Price3.090 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float18.241M | EPS-2.520 |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-03-08 | ||||||
REV |
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.440 | -0.400 | 0.0400 | ||||
REV | 140.000K | 359.000K | 219.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Lyra Therapeutics (NASDAQ: LYRA) through any online brokerage.
Other companies in Lyra Therapeutics’s space includes: Opiant Pharma (NASDAQ:OPNT), SCYNEXIS (NASDAQ:SCYX), Ocuphire Pharma (NASDAQ:OCUP), Longboard Pharmaceuticals (NASDAQ:LBPH) and Qilian Intl Hldg Gr (NASDAQ:QLI).
The latest price target for Lyra Therapeutics (NASDAQ: LYRA) was reported by Cantor Fitzgerald on Tuesday, May 24, 2022. The analyst firm set a price target for 15.00 expecting LYRA to rise to within 12 months (a possible 441.57% upside). 1 analyst firms have reported ratings in the last year.
The stock price for Lyra Therapeutics (NASDAQ: LYRA) is $2.7697 last updated Today at January 31, 2023 at 3:39 PM UTC.
There are no upcoming dividends for Lyra Therapeutics.
Lyra Therapeutics’s Q4 earnings are confirmed for Wednesday, March 8, 2023.
There is no upcoming split for Lyra Therapeutics.
Lyra Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
Lyra Therapeutics Stock (NASDAQ: LYRA) stock price, news, charts, stock research, profile.
Day Range2.680 - 2.800 | 52 Wk Range2.350 - 8.180 | Open / Close2.780 / - | Float / Outstanding18.241M / 31.827M |
Vol / Avg.15.924K / 66.137K | Mkt Cap88.151M | P/E- | 50d Avg. Price3.090 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float18.241M | EPS-2.520 |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-03-08 | ||||||
REV |
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.440 | -0.400 | 0.0400 | ||||
REV | 140.000K | 359.000K | 219.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Lyra Therapeutics (NASDAQ: LYRA) through any online brokerage.
Other companies in Lyra Therapeutics’s space includes: Opiant Pharma (NASDAQ:OPNT), SCYNEXIS (NASDAQ:SCYX), Ocuphire Pharma (NASDAQ:OCUP), Longboard Pharmaceuticals (NASDAQ:LBPH) and Qilian Intl Hldg Gr (NASDAQ:QLI).
The latest price target for Lyra Therapeutics (NASDAQ: LYRA) was reported by Cantor Fitzgerald on Tuesday, May 24, 2022. The analyst firm set a price target for 15.00 expecting LYRA to rise to within 12 months (a possible 441.57% upside). 1 analyst firms have reported ratings in the last year.
The stock price for Lyra Therapeutics (NASDAQ: LYRA) is $2.7697 last updated Today at January 31, 2023 at 3:39 PM UTC.
There are no upcoming dividends for Lyra Therapeutics.
Lyra Therapeutics’s Q4 earnings are confirmed for Wednesday, March 8, 2023.
There is no upcoming split for Lyra Therapeutics.
Lyra Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
Lyra Therapeutics Stock (NASDAQ: LYRA) stock price, news, charts, stock research, profile.
Day Range2.680 - 2.800 | 52 Wk Range2.350 - 8.180 | Open / Close2.780 / - | Float / Outstanding18.241M / 31.827M |
Vol / Avg.15.924K / 66.137K | Mkt Cap88.151M | P/E- | 50d Avg. Price3.090 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float18.241M | EPS-2.520 |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-03-08 | ||||||
REV |
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.440 | -0.400 | 0.0400 | ||||
REV | 140.000K | 359.000K | 219.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Lyra Therapeutics (NASDAQ: LYRA) through any online brokerage.
Other companies in Lyra Therapeutics’s space includes: Opiant Pharma (NASDAQ:OPNT), SCYNEXIS (NASDAQ:SCYX), Ocuphire Pharma (NASDAQ:OCUP), Longboard Pharmaceuticals (NASDAQ:LBPH) and Qilian Intl Hldg Gr (NASDAQ:QLI).
The latest price target for Lyra Therapeutics (NASDAQ: LYRA) was reported by Cantor Fitzgerald on Tuesday, May 24, 2022. The analyst firm set a price target for 15.00 expecting LYRA to rise to within 12 months (a possible 441.57% upside). 1 analyst firms have reported ratings in the last year.
The stock price for Lyra Therapeutics (NASDAQ: LYRA) is $2.7697 last updated Today at January 31, 2023 at 3:39 PM UTC.
There are no upcoming dividends for Lyra Therapeutics.
Lyra Therapeutics’s Q4 earnings are confirmed for Wednesday, March 8, 2023.
There is no upcoming split for Lyra Therapeutics.
Lyra Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
Lyra Therapeutics Stock (NASDAQ: LYRA) stock price, news, charts, stock research, profile.
Day Range2.680 - 2.800 | 52 Wk Range2.350 - 8.180 | Open / Close2.780 / - | Float / Outstanding18.241M / 31.827M |
Vol / Avg.15.924K / 66.137K | Mkt Cap88.151M | P/E- | 50d Avg. Price3.090 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float18.241M | EPS-2.520 |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-03-08 | ||||||
REV |
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.440 | -0.400 | 0.0400 | ||||
REV | 140.000K | 359.000K | 219.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Lyra Therapeutics (NASDAQ: LYRA) through any online brokerage.
Other companies in Lyra Therapeutics’s space includes: Opiant Pharma (NASDAQ:OPNT), SCYNEXIS (NASDAQ:SCYX), Ocuphire Pharma (NASDAQ:OCUP), Longboard Pharmaceuticals (NASDAQ:LBPH) and Qilian Intl Hldg Gr (NASDAQ:QLI).
The latest price target for Lyra Therapeutics (NASDAQ: LYRA) was reported by Cantor Fitzgerald on Tuesday, May 24, 2022. The analyst firm set a price target for 15.00 expecting LYRA to rise to within 12 months (a possible 441.57% upside). 1 analyst firms have reported ratings in the last year.
The stock price for Lyra Therapeutics (NASDAQ: LYRA) is $2.7697 last updated Today at January 31, 2023 at 3:39 PM UTC.
There are no upcoming dividends for Lyra Therapeutics.
Lyra Therapeutics’s Q4 earnings are confirmed for Wednesday, March 8, 2023.
There is no upcoming split for Lyra Therapeutics.
Lyra Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
Lyra Therapeutics Stock (NASDAQ: LYRA) stock price, news, charts, stock research, profile.
Day Range2.680 - 2.800 | 52 Wk Range2.350 - 8.180 | Open / Close2.780 / - | Float / Outstanding18.241M / 31.827M |
Vol / Avg.15.924K / 66.137K | Mkt Cap88.151M | P/E- | 50d Avg. Price3.090 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float18.241M | EPS-2.520 |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-03-08 | ||||||
REV |
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.440 | -0.400 | 0.0400 | ||||
REV | 140.000K | 359.000K | 219.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Lyra Therapeutics (NASDAQ: LYRA) through any online brokerage.
Other companies in Lyra Therapeutics’s space includes: Opiant Pharma (NASDAQ:OPNT), SCYNEXIS (NASDAQ:SCYX), Ocuphire Pharma (NASDAQ:OCUP), Longboard Pharmaceuticals (NASDAQ:LBPH) and Qilian Intl Hldg Gr (NASDAQ:QLI).
The latest price target for Lyra Therapeutics (NASDAQ: LYRA) was reported by Cantor Fitzgerald on Tuesday, May 24, 2022. The analyst firm set a price target for 15.00 expecting LYRA to rise to within 12 months (a possible 441.57% upside). 1 analyst firms have reported ratings in the last year.
The stock price for Lyra Therapeutics (NASDAQ: LYRA) is $2.7697 last updated Today at January 31, 2023 at 3:39 PM UTC.
There are no upcoming dividends for Lyra Therapeutics.
Lyra Therapeutics’s Q4 earnings are confirmed for Wednesday, March 8, 2023.
There is no upcoming split for Lyra Therapeutics.
Lyra Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
Lyra Therapeutics Stock (NASDAQ: LYRA) stock price, news, charts, stock research, profile.
Day Range2.680 - 2.800 | 52 Wk Range2.350 - 8.180 | Open / Close2.780 / - | Float / Outstanding18.241M / 31.827M |
Vol / Avg.15.924K / 66.137K | Mkt Cap88.151M | P/E- | 50d Avg. Price3.090 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float18.241M | EPS-2.520 |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-03-08 | ||||||
REV |
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.440 | -0.400 | 0.0400 | ||||
REV | 140.000K | 359.000K | 219.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Lyra Therapeutics (NASDAQ: LYRA) through any online brokerage.
Other companies in Lyra Therapeutics’s space includes: Opiant Pharma (NASDAQ:OPNT), SCYNEXIS (NASDAQ:SCYX), Ocuphire Pharma (NASDAQ:OCUP), Longboard Pharmaceuticals (NASDAQ:LBPH) and Qilian Intl Hldg Gr (NASDAQ:QLI).
The latest price target for Lyra Therapeutics (NASDAQ: LYRA) was reported by Cantor Fitzgerald on Tuesday, May 24, 2022. The analyst firm set a price target for 15.00 expecting LYRA to rise to within 12 months (a possible 441.57% upside). 1 analyst firms have reported ratings in the last year.
The stock price for Lyra Therapeutics (NASDAQ: LYRA) is $2.7697 last updated Today at January 31, 2023 at 3:39 PM UTC.
There are no upcoming dividends for Lyra Therapeutics.
Lyra Therapeutics’s Q4 earnings are confirmed for Wednesday, March 8, 2023.
There is no upcoming split for Lyra Therapeutics.
Lyra Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
Lyra Therapeutics Stock (NASDAQ: LYRA) stock price, news, charts, stock research, profile.
Day Range2.680 - 2.800 | 52 Wk Range2.350 - 8.180 | Open / Close2.780 / - | Float / Outstanding18.241M / 31.827M |
Vol / Avg.15.924K / 66.137K | Mkt Cap88.151M | P/E- | 50d Avg. Price3.090 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float18.241M | EPS-2.520 |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-03-08 | ||||||
REV |
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.440 | -0.400 | 0.0400 | ||||
REV | 140.000K | 359.000K | 219.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Lyra Therapeutics (NASDAQ: LYRA) through any online brokerage.
Other companies in Lyra Therapeutics’s space includes: Opiant Pharma (NASDAQ:OPNT), SCYNEXIS (NASDAQ:SCYX), Ocuphire Pharma (NASDAQ:OCUP), Longboard Pharmaceuticals (NASDAQ:LBPH) and Qilian Intl Hldg Gr (NASDAQ:QLI).
The latest price target for Lyra Therapeutics (NASDAQ: LYRA) was reported by Cantor Fitzgerald on Tuesday, May 24, 2022. The analyst firm set a price target for 15.00 expecting LYRA to rise to within 12 months (a possible 441.57% upside). 1 analyst firms have reported ratings in the last year.
The stock price for Lyra Therapeutics (NASDAQ: LYRA) is $2.7697 last updated Today at January 31, 2023 at 3:39 PM UTC.
There are no upcoming dividends for Lyra Therapeutics.
Lyra Therapeutics’s Q4 earnings are confirmed for Wednesday, March 8, 2023.
There is no upcoming split for Lyra Therapeutics.
Lyra Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.